HDAC6 inhibitor accelerates wound healing by inhibiting tubulin mediated IL-1β secretion in diabetic mice
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1866 (11) , 165903
Abstract
No abstract availableKeywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology
- Anusandhan National Research Foundation
This publication has 41 references indexed in Scilit:
- Treating inflammation by blocking interleukin-1 in a broad spectrum of diseasesNature Reviews Drug Discovery, 2012
- Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophagesProceedings of the National Academy of Sciences, 2012
- Inflammation and wound healing: the role of the macrophageExpert Reviews in Molecular Medicine, 2011
- Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin AJournal of the American Chemical Society, 2010
- Macrophage Dysfunction Impairs Resolution of Inflammation in the Wounds of Diabetic MicePLOS ONE, 2010
- IIp45 Inhibits Cell Migration through Inhibition of HDAC6Journal of Biological Chemistry, 2010
- HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulationProceedings of the National Academy of Sciences, 2008
- The Antiinflammatory Cytokine Interleukin-1 Receptor Antagonist Protects from High-Fat Diet-Induced HyperglycemiaEndocrinology, 2008
- Cellular and molecular basis of wound healing in diabetesJournal of Clinical Investigation, 2007
- Histone deacetylase inhibitors prevent exocytosis of interleukin-1β-containing secretory lysosomes: role of microtubulesBlood, 2006